Products - Children and teenagers | Topic

Showing 31 products

Date | Title

Status: Topic selectionRemove ‘Status: Topic selection’ filter

Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for children with severe atopic dermatitis [TSID10434]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant [TS ID 11868]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Paediatric lymphatic interventions (mainly Percutaneous thoracic duct embolisation) for Chylothorax, chylous ascites, plastic bronchitis, chylopericardium, Chyluria, Protein losing enteropathy
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intention
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years [ID6554]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC

What we do

Into practice

Who we are

Children and teenagers Products

Showing 31 products

Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]

Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]

Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]

Dupilumab for children with severe atopic dermatitis [TSID10434]

Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]

Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]

Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]

Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]

Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]

Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]

Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]

Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827]

Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant [TS ID 11868]

Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]

Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]

Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]

Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]

Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]

Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]

Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106

Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]

Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]

Paediatric lymphatic interventions (mainly Percutaneous thoracic duct embolisation) for Chylothorax, chylous ascites, plastic bronchitis, chylopericardium, Chyluria, Protein losing enteropathy

NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intention

Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years [ID6554]

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Children and teenagers Products

Showing 31 products